文献速递神经核医学肿瘤 PET/CT

迈向通用18F-淀粉样蛋白示踪剂视觉判读协议:CAPTAINs研究

Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study.
PubMed 文献 · J Nucl Med · 2021-03-12

该概念验证研究让4名专家和3名非专家读片者,对18F-florbetaben、18F-florbetapir和18F-flutemetamol三种示踪剂的扫描图像,分别按三种已批准的视觉判读协议进行判读,并计算读片者间一致性、信度及与定量SUV比阈值的符合率。结果显示专家组的各协议间无显著差异,非专家组则存在显著差异且总体准确率中等至一般,提示通用视觉评估协议可行。

要点

  • 专家组使用三种已批准视觉判读协议时,各一致性指标无显著差异。
  • 非专家组中不同协议间存在显著差异,总体准确率中等至一般。
  • 研究表明淀粉样蛋白PET视觉判读可标准化,通用协议对经验较少者尤其有益。

核心结论

  • 尽管使用不同的已批准视觉判读协议,三种18F-淀粉样蛋白示踪剂的读片者间一致性仍较高。
  • 专家组的视觉判读结果不依赖于所用判读协议,提示通用视觉评估协议可行。
  • 非专家组中不同协议间存在显著差异,总体准确率中等至一般。

研究设计与样本

  • 国际多中心概念验证研究,纳入4名专家和3名非专家读片者。
  • 对18F-florbetaben、18F-florbetapir和18F-flutemetamol三种示踪剂的扫描图像进行判读。
  • 每张扫描按随机顺序由每位读片者依据三种已批准视觉判读协议分别判读。
  • 读片者对所用示踪剂设盲,并将每张扫描判为阳性或阴性,每次判读后给出信心判断。
  • 计算视觉读片者一致百分比、读片者间信度及与二分类定量指标(固定SUV比值阈值)的符合率,并分别对专家和非专家组分析。

主要发现

  • 专家组中,使用不同已批准视觉判读协议在各一致性指标上均无显著差异。
  • 名义差异提示18F-florbetaben视觉判读协议在读片者间信度和准确率上最高,尤其在低信心条件下。
  • 非专家读片者组中,不同视觉判读协议间存在显著差异,总体准确率中等至一般。
  • 非专家读片者组中,18F-florbetapir视觉判读协议的信度最高。

关键数值与推荐

  • 三种已批准视觉判读协议分别对应18F-florbetaben、18F-florbetapir和18F-flutemetamol。
  • 二分类定量指标采用固定SUV比值阈值判定阳性或阴性扫描。
  • 专家读片者4名,非专家读片者3名。

临床怎么用

  • 专家读片时,三种已批准协议对18F-淀粉样蛋白示踪剂的视觉判读结果一致性较高,可互换使用。
  • 非专家读片时,不同协议间存在显著差异,应关注协议选择对判读准确性的影响。
  • 通用视觉评估协议的建立可能有助于标准化淀粉样蛋白PET判读,尤其惠及经验较少的读片者。

局限性

  • 本研究为概念验证研究,样本量有限(专家4名、非专家3名)。
  • 原文未报告读片者间信度、准确率等指标的具体数值及统计检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To date, 3 18F-labeled PET tracers have been approved for assessing cerebral amyloid plaque pathology in the diagnostic workup of suspected Alzheimer disease (AD). Although scanning protocols are relatively similar across tracers, U.S. Food and Drug Administration- and the European Medicines Agency-approved visual rating protocols differ among the 3 tracers. This proof-of-concept study assessed the comparability of the 3 approved visual rating protocols to classify a scan as amyloid-positive or -negative, when applied by groups of experts and nonexperts to all 3 amyloid tracers. Methods: In an international multicenter approach, both expert (n = 4) and nonexpert raters (n = 3) rated scans acquired with 18F-florbetaben, 18F-florbetapir and 18F-flutemetamol. Scans obtained with each tracer were presented for reading according to all 3 approved visual rating protocols. In a randomized order, every single scan was rated by each reader according to all 3 protocols. Raters were blinded for the amyloid tracer used and asked to rate each scan as positive or negative, giving a confidence judgment after each response. Percentage of visual reader agreement, interrater reliability, and agreement of each visual read with binary quantitative measures (fixed SUV ratio threshold for positive or negative scans) were computed. These metrics were analyzed separately for expert and nonexpert groups. Results: No significant differences in using the different approved visual rating protocols were observed across the different metrics of agreement in the group of experts. Nominal differences suggested that the 18F-florbetaben visual rating protocol achieved the highest interrater reliability and accuracy especially under low confidence conditions. For the group of nonexpert raters, significant differences between the different visual rating protocols were observed with overall moderate-to-fair accuracy and with the highest reliability for the 18F-florbetapir visual rating protocol. Conclusion: We observed high interrater agreement despite applying different visual rating protocols for all 18F-labeled amyloid tracers. This implies that the results of the visual interpretation of amyloid imaging can be well standardized and do not depend on the rating protocol in experts. Consequently, the creation of a universal visual assessment protocol for all amyloid imaging tracers appears feasible, which could benefit especially the less-experienced readers.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bischof GN, Bartenstein P, Barthel H, et al. Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study. J Nucl Med. 2021. PMID: 33712532. doi:10.2967/jnumed.120.250290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。